These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2905479)

  • 1. Are D1 dopamine receptor agonists potential antidepressants?
    Serra G; Collu M; D'Aquila P; Pani L; Gessa GL
    Pharmacol Res Commun; 1988 Dec; 20(12):1121-2. PubMed ID: 2905479
    [No Abstract]   [Full Text] [Related]  

  • 2. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression.
    D'Aquila PS; Collu M; Pani L; Gessa GL; Serra G
    Eur J Pharmacol; 1994 Sep; 262(1-2):107-11. PubMed ID: 7813561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM; Cereska KS
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats.
    Meyer ME; Shults JM
    Pharmacol Biochem Behav; 1993 Oct; 46(2):269-74. PubMed ID: 7903456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
    Pettersson I; Liljefors T; Bøgesø K
    J Med Chem; 1990 Aug; 33(8):2197-204. PubMed ID: 1973733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated stimulation of dopamine D1 receptors enhances the effects of dopamine receptor agonists.
    White FJ; Hu XT; Brooderson RJ
    Eur J Pharmacol; 1990 Dec; 191(3):497-9. PubMed ID: 1982272
    [No Abstract]   [Full Text] [Related]  

  • 9. Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
    Neumeyer JL; Kula NS; Baldessarini RJ; Baindur N
    J Med Chem; 1992 Apr; 35(8):1466-71. PubMed ID: 1533424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKF 38393: vacillatory behavior in immature rats.
    Molino LJ; Shemer A; Whitaker-Azmitia PM
    Eur J Pharmacol; 1989 Feb; 161(2-3):223-5. PubMed ID: 2566489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of D1 and D2 antagonists on the transient increase of dopamine release by dopamine agonists by means of brain dialysis.
    Kurata K; Shibata R
    Neurosci Lett; 1991 Nov; 133(1):77-80. PubMed ID: 1686482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
    Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific D1 and D2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model in the rat.
    Rouillard C; Bédard PJ
    Neuropharmacology; 1988 Dec; 27(12):1257-64. PubMed ID: 2907616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship.
    Neumeyer JL; Baindur N; Niznik HB; Guan HC; Seeman P
    J Med Chem; 1991 Dec; 34(12):3366-71. PubMed ID: 1684995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excitatory and inhibitory action of dopamine on hippocampal neurons in vitro. Involvement of D2 and D1 receptors.
    Smiałowski A; Bijak M
    Neuroscience; 1987 Oct; 23(1):95-101. PubMed ID: 2960914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434.
    Abrahams BS; Rutherford JD; Mallet PE; Beninger RJ
    Eur J Pharmacol; 1998 Feb; 343(2-3):111-8. PubMed ID: 9570457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors.
    Koller WC; Herbster G
    Clin Neuropharmacol; 1988 Jun; 11(3):221-31. PubMed ID: 3261198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.